Khalid Islam
Director · Gain Therapeutics, Inc.
Individual
- 2025
- Jul 17, 2026
- 3
Other insiders active in the same sector
No other insider has filed at Khalid Islam's companies, so these are insiders reporting open-market trades at other companies in the same sector.
- James E. Flynn - $70.87M in NUVL purchases and sales in the last 12 months
- RA CAPITAL MANAGEMENT, L.P. - $69.43M in VOR purchases and sales in the last 12 months
- Joaquin Duato - $66.84M in JNJ purchases and sales in the last 12 months
- Eric Venker - $65.62M in ROIV purchases and sales in the last 12 months
- EcoR1 Capital, LLC - $65.00M in TRAX purchases and sales in the last 12 months
- Forbion Growth Opportunities Fund III Cooperatief U.A. - $64.80M in BRVE purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Khalid Islam?
Khalid Islam is a corporate insider, tracked as Director of Gain Therapeutics, Inc. (GANX). InsiderAlpha holds 3 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Khalid Islam submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.